Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article describes a non-blinded study investigating low level laser therapy for seven patients but reports no new clinical findings.

This study found that the decision board is a reliable and valid tool for assessing treatment preferences in systemic lupus erythematosus patients, who tended to favor oral medication due to concerns about side effects.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

This study found that certain lncRNA gene polymorphisms in HOTAIR and MALAT1 are associated with increased susceptibility to systemic lupus erythematosus, potentially informing clinical applications.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This review of Lawsonia inermis L., or henna, details its bioactive compounds and historical uses in Unani medicine, including treatment for various conditions like ulcers and jaundice, while highlighting its potential for wound healing, hepatoprotective, and other effects, though further research is needed.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

This review discusses valproic acid as a common antiseizure medication associated with alopecia and highlights the need for its inclusion in relevant medical guides, without presenting new clinical findings.

This case report details a post-menopausal woman with hirsutism and virilization due to rare Leydig cell tumors in both ovaries, underscoring the challenge of detecting such tumors with standard imaging.

This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.

This review discusses the potential of lecithin organogels for improving topical drug delivery and presents no new experimental results; the authors highlight their stability and low skin irritancy as advantages.

This letter highlights the challenge of implementing ethical principles in healthcare due to society's dependence on financial systems, suggesting this may hinder public health and environmental well-being.

This study reported that belimumab helped over 40% of active systemic lupus erythematosus patients achieve low disease activity, with more than 20% able to stop glucocorticoids completely.

This study found that long-lived proteins in mice, identified across various tissues, may be linked to neurodegenerative and cardiovascular diseases due to their low renewal rate and increased risk of damage.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study developed a rapid and efficient in vitro method using high-performance liquid chromatography to screen for steroid 5 alpha-reductase inhibitors, determining inhibition constants for Finasteride and Epristeride.

This study reported the development of a novel and reliable liquid chromatographic method to measure testosterone and epitestosterone in human urine, offering sensitive detection for doping control.

This study reports that a patient with rare linear lichen planopilaris experienced complete hair regrowth after 12 weeks of treatment with the antibody ixekizumab, suggesting it as a potential targeted therapy.

This review discusses the consensus reached by international experts on guidelines for prescribing and monitoring low-dose oral minoxidil for hair loss, and reports no new clinical results.

This article is a medical index book on disorders in obstetric practice and reports no new clinical results.

This review examines the molecular effects of photobiomodulation therapy, particularly its influence on gene and protein expression related to inflammation and cell functions, but reports no new clinical results.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

Baricitinib is a safe and effective treatment for severe alopecia areata.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.